Artificial Blood Market Strategic Assessment And Forecast 2018-2026
Artificial blood is
an artificially developed substitute for red blood cells. For
decades, scientists have been trying to develop artificial blood from
various sources and through different methods to address the shortage
of blood for transfusions. Inadequate number of blood donors and the
criticality of blood-type rejection have encouraged researchers to
develop artificial blood, thus reducing the dependency on blood
donors.
Transfusion of red
blood cells (RBCs) is a standard and indispensable therapy for anemic
conditions. Blood transfusion process has progressed through various
developments, including development of acid-citrate-dextrose blood
preservation solution, and cloning of ABO gene. However, blood
transfusion come with a high risk of infections. Recombinant
erythropoietin stimulating agent therapy has been the prominent
therapy in cases such as chronic kidney disease, and chronic anemic
conditions. Yet in thrombotic and neoplastic complications, blood
transfusion is the only option. Hence, RBC production from
hematopoietic stem cells has been the focus of regenerative therapy,
with major players investing billions of dollars in R&D related
to this technique. However, the final product is yet to receive U.S.
Food & Drug Administration (FDA) approval.
Request For a
Sample Copy of This Research Report:
https://www.coherentmarketinsights.com/insight/request-sample/11
Artificial
Blood Market Development
There has been
significant progress made in the global artificial blood market with
respect to finding a suitable method to produce blood cells.
Scientists have been trying to develop artificial blood from diverse
molecules ranging from perfluorocarbons to hemoglobin. With the
advent of research in stem cells, researchers began to develop RBCs
from stem cells of cord blood. The enrollment for the first clinical
trials of stem-cell based red blood cells began in 2009. This study
used stem cells from cord blood and adult bone marrow. The study was
conducted at the Hematological Laboratory at the University of Paris
VI.
A similar research
conducted by scientists at the University of Bristol and the UK’s
National Health Service (NHS) using stem cells from adult and
umbilical cord blood has shown successful results from initial
studies. The study is scheduled to enter clinical trials with 20
subjects in 2017. The focus of these trials is to provide special
treatment for specific patient groups, rather than act as complete
replacement for blood.
Artificial
Blood Market Potential
According to the
World Health Organization (WHO), there are around 50,000 stem cell
transplantations performed annually worldwide, which include 2,000
cord blood hematopoietic stem cell transplants performed each year.
Use of stem cells from cord blood is increasing, as it does not
require perfect human leukocyte antigen (HLA) tissue matching, can be
used allogenically, and has less incidence of graft v/s host disease.
According to the New York Blood Center (NYBC), which is the largest
cord blood bank globally in terms of units stored, over half of all
stem cell transplants in children, in the U.S., use cord blood. A
similar statistic has been noted among adults in Japan.
Post the trial in
2017, production is expected to commence in the following 8 to 10
years, thus prolonging the commercialization of product in the
artificial blood market.
Artificial
Blood Market Future Outlook
Cord blood stem cell
transplantation has proved to be a successful therapy in treatment of
around 70 diseases. Developing artificial blood can be of great aid
to meet the demand-supply gap in blood transfusion, more so
considering the fact that finding compatible donors for sickle cell
anemia and thalassemia patients is a mammoth task. Development of
artificial blood could be the most viable solution to address the
unmet needs among these patients. Continued investment in research
and development is crucial for ensuring the commercial application of
this technology, a very critical factor to contribute towards
development of artificial blood market. Being a critical therapy for
a severe life condition, the artificial blood market is expected to
get a product in a decade or so.
Click To Read
More On Artificial
Blood Market
About Coherent
Market Insights:
Coherent Market Insights is a prominent market research and
consulting firm offering action-ready syndicated research reports,
custom market analysis, consulting services, and competitive analysis
through various recommendations related to emerging market trends,
technologies, and potential absolute dollar opportunity.
Comments
Post a Comment